Compilation of References in Leaders in Pharmaceutical Intelligence about
proteomics, metabolomics, signaling pathways, and cell regulation
Curator: Larry H. Bernstein, MD, FCAP
Proteomics
- The Human Proteome Map Completed
Reporter and Curator: Larry H. Bernstein, MD, FCAP
http://pharmaceuticalintelligence.com/2014/08/28/the-human-proteome-map-completed/
- Proteomics – The Pathway to Understanding and Decision-making in Medicine
Author and Curator, Larry H Bernstein, MD, FCAP
http://pharmaceuticalintelligence.com/2014/06/24/proteomics-the-pathway-to-understanding-and-decision-making-in-medicine/
- Advances in Separations Technology for the “OMICs” and Clarification of Therapeutic Targets
Author and Curator, Larry H Bernstein, MD, FCAP
http://pharmaceuticalintelligence.com/2012/10/22/advances-in-separations-technology-for-the-omics-and-clarification-of-therapeutic-targets/
- Expanding the Genetic Alphabet and Linking the Genome to the Metabolome
Author and Curator, Larry H Bernstein, MD, FCAP
http://pharmaceuticalintelligence.com/2012/09/24/expanding-the-genetic-alphabet-and-linking-the-genome-to-the-metabolome/
- Synthesizing Synthetic Biology: PLOS Collections
Reporter: Aviva Lev-Ari
http://pharmaceuticalintelligence.com/2012/08/17/synthesizing-synthetic-biology-plos-collections/
Metabolomics
- Extracellular evaluation of intracellular flux in yeast cells
Larry H. Bernstein, MD, FCAP, Reviewer and Curator
http://pharmaceuticalintelligence.com/2014/08/25/extracellular-evaluation-of-intracellular-flux-in-yeast-cells/ - Metabolomic analysis of two leukemia cell lines. I.
Larry H. Bernstein, MD, FCAP, Reviewer and Curator
http://pharmaceuticalintelligence.com/2014/08/23/metabolomic-analysis-of-two-leukemia-cell-lines-_i/ - Metabolomic analysis of two leukemia cell lines. II.
Larry H. Bernstein, MD, FCAP, Reviewer and Curator
http://pharmaceuticalintelligence.com/2014/08/24/metabolomic-analysis-of-two-leukemia-cell-lines-ii/ - Metabolomics, Metabonomics and Functional Nutrition: the next step in nutritional metabolism and biotherapeutics
Reviewer and Curator, Larry H. Bernstein, MD, FCAP
http://pharmaceuticalintelligence.com/2014/08/22/metabolomics-metabonomics-and-functional-nutrition-the-next-step-in-nutritional-metabolism-and-biotherapeutics/ - Buffering of genetic modules involved in tricarboxylic acid cycle metabolism provides homeomeostatic regulation
Larry H. Bernstein, MD, FCAP, Reviewer and curator
http://pharmaceuticalintelligence.com/2014/08/27/buffering-of-genetic-modules-involved-in-tricarboxylic-acid-cycle-metabolism-provides-homeomeostatic-regulation/
Metabolic Pathways
- Pentose Shunt, Electron Transfer, Galactose, more Lipids in brief
Reviewer and Curator: Larry H. Bernstein, MD, FCAP
http://pharmaceuticalintelligence.com/2014/08/21/pentose-shunt-electron-transfer-galactose-more-lipids-in-brief/ - Mitochondria: More than just the “powerhouse of the cell”
Reviewer and Curator: Ritu Saxena
http://pharmaceuticalintelligence.com/2012/07/09/mitochondria-more-than-just-the-powerhouse-of-the-cell/ - Mitochondrial fission and fusion: potential therapeutic targets?
Reviewer and Curator: Ritu saxena
http://pharmaceuticalintelligence.com/2012/10/31/mitochondrial-fission-and-fusion-potential-therapeutic-target/ - Mitochondrial mutation analysis might be “1-step” away
Reviewer and Curator: Ritu Saxena
http://pharmaceuticalintelligence.com/2012/08/14/mitochondrial-mutation-analysis-might-be-1-step-away/ - Selected References to Signaling and Metabolic Pathways in PharmaceuticalIntelligence.com
Curator: Larry H. Bernstein, MD, FCAP
http://pharmaceuticalintelligence.com/2014/08/14/selected-references-to-signaling-and-metabolic-pathways-in-leaders-in-pharmaceutical-intelligence/ - Metabolic drivers in aggressive brain tumors
Prabodh Kandal, PhD
http://pharmaceuticalintelligence.com/2012/11/11/metabolic-drivers-in-aggressive-brain-tumors/ - Metabolite Identification Combining Genetic and Metabolic Information: Genetic association links unknown metabolites to functionally related genes
Author and Curator: Aviva Lev-Ari, PhD, RD
http://pharmaceuticalintelligence.com/2012/10/22/metabolite-identification-combining-genetic-and-metabolic-information-genetic-association-links-unknown-metabolites-to-functionally-related-genes/ - Mitochondria: Origin from oxygen free environment, role in aerobic glycolysis, metabolic adaptation
Author and curator:Larry H Bernstein, MD, FCAP
http://pharmaceuticalintelligence.com/2012/09/26/mitochondria-origin-from-oxygen-free-environment-role-in-aerobic-glycolysis-metabolic-adaptation/ - Therapeutic Targets for Diabetes and Related Metabolic Disorders
Reporter, Aviva Lev-Ari, PhD, RD
http://pharmaceuticalintelligence.com/2012/08/20/therapeutic-targets-for-diabetes-and-related-metabolic-disorders/ - Buffering of genetic modules involved in tricarboxylic acid cycle metabolism provides homeomeostatic regulation
Larry H. Bernstein, MD, FCAP, Reviewer and curator
http://pharmaceuticalintelligence.com/2014/08/27/buffering-of-genetic-modules-involved-in-tricarboxylic-acid-cycle-metabolism-provides-homeomeostatic-regulation/ - The multi-step transfer of phosphate bond and hydrogen exchange energy
Curator:Larry H. Bernstein, MD, FCAP,
http://pharmaceuticalintelligence.com/2014/08/19/the-multi-step-transfer-of-phosphate-bond-and-hydrogen-exchange-energy/ - Studies of Respiration Lead to Acetyl CoA
Author and Curator: Larry H. Bernstein, MD, FCAP
http://pharmaceuticalintelligence.com/2014/08/18/studies-of-respiration-lead-to-acetyl-coa/ - Lipid Metabolism
Author and Curator: Larry H. Bernstein, MD, FCAP
http://pharmaceuticalintelligence.com/2014/08/15/lipid-metabolism/ - Carbohydrate Metabolism
Author and Curator: Larry H. Bernstein, MD, FCAP
http://pharmaceuticalintelligence.com/2014/08/13/carbohydrate-metabolism/ - Prologue to Cancer – e-book Volume One – Where are we in this journey?
Author and Curator: Larry H. Bernstein, MD, FCAP
http://pharmaceuticalintelligence.com/2014/04/13/prologue-to-cancer-ebook-4-where-are-we-in-this-journey/ - Introduction – The Evolution of Cancer Therapy and Cancer Research: How We Got Here?
Author and Curator: Larry H. Bernstein, MD, FCAP
http://pharmaceuticalintelligence.com/2014/04/04/introduction-the-evolution-of-cancer-therapy-and-cancer-research-how-we-got-here/ - Inhibition of the Cardiomyocyte-Specific Kinase TNNI3K
Author and Curator: Larry H. Bernstein, MD, FCAP
http://pharmaceuticalintelligence.com/2013/11/01/inhibition-of-the-cardiomyocyte-specific-kinase-tnni3k/ - The Binding of Oligonucleotides in DNA and 3-D Lattice Structures
Author and Curator: Larry H. Bernstein, MD, FCAP
http://pharmaceuticalintelligence.com/2013/05/15/the-binding-of-oligonucleotides-in-dna-and-3-d-lattice-structures/ - Mitochondrial Metabolism and Cardiac Function
Author and Curator: Larry H. Bernstein, MD, FCAP
http://pharmaceuticalintelligence.com/2013/04/14/mitochondrial-metabolism-and-cardiac-function/ - How Methionine Imbalance with Sulfur-Insufficiency Leads to Hyperhomocysteinemia
Curator: Larry H. Bernstein, MD, FCAP
http://pharmaceuticalintelligence.com/2013/04/04/sulfur-deficiency-leads_to_hyperhomocysteinemia/ - AMPK Is a Negative Regulator of the Warburg Effect and Suppresses Tumor Growth In Vivo
Author and Curator: SJ. Williams
http://pharmaceuticalintelligence.com/2013/03/12/ampk-is-a-negative-regulator-of-the-warburg-effect-and-suppresses-tumor-growth-in-vivo/ - A Second Look at the Transthyretin Nutrition Inflammatory Conundrum
Author and Curator: Larry H. Bernstein, MD, FCAP
http://pharmaceuticalintelligence.com/2012/12/03/a-second-look-at-the-transthyretin-nutrition-inflammatory-conundrum/ - Overview of Posttranslational Modification (PTM)
Writer and Curator: Larry H. Bernstein, MD, FCAP
http://pharmaceuticalintelligence.com/2014/07/29/overview-of-posttranslational-modification-ptm/ - Malnutrition in India, high newborn death rate and stunting of children age under five years
Writer and Curator: Larry H. Bernstein, MD, FCAP
http://pharmaceuticalintelligence.com/2014/07/15/malnutrition-in-india-high-newborn-death-rate-and-stunting-of-children-age-under-five-years/ - Update on mitochondrial function, respiration, and associated disorders
Writer and Curator: Larry H. Bernstein, MD, FCAP
http://pharmaceuticalintelligence.com/2014/07/08/update-on-mitochondrial-function-respiration-and-associated-disorders/ - Omega-3 fatty acids, depleting the source, and protein insufficiency in renal disease
Larry H. Bernstein, MD, FCAP, Curator
http://pharmaceuticalintelligence.com/2014/07/06/omega-3-fatty-acids-depleting-the-source-and-protein-insufficiency-in-renal-disease/ - Late Onset of Alzheimer’s Disease and One-carbon Metabolism
Reporter and Curator: Dr. Sudipta Saha, Ph.D.
http://pharmaceuticalintelligence.com/2013/05/06/alzheimers-disease-and-one-carbon-metabolism/ - Problems of vegetarianism
Reporter and Curator: Dr. Sudipta Saha, Ph.D.
http://pharmaceuticalintelligence.com/2013/04/22/problems-of-vegetarianism/
Signaling Pathways
- Introduction to e-Series A: Cardiovascular Diseases, Volume Four Part 2: Regenerative Medicine
Larry H. Bernstein, MD, FCAP, writer, and Aviva Lev- Ari, PhD, RN http://pharmaceuticalintelligence.com/2014/04/27/larryhbernintroduction_to_cardiovascular_diseases-translational_medicine-part_2/ - Epilogue: Envisioning New Insights in Cancer Translational Biology
Series C: e-Books on Cancer & Oncology
Author & Curator: Larry H. Bernstein, MD, FCAP, Series C Content Consultant
http://pharmaceuticalintelligence.com/2014/03/29/epilogue-envisioning-new-insights/ - Ca2+-Stimulated Exocytosis: The Role of Calmodulin and Protein Kinase C in Ca2+ Regulation of Hormone and Neurotransmitter Writer and Curator: Larry H Bernstein, MD, FCAP and Curator and Content Editor: Aviva Lev-Ari, PhD, RN
http://pharmaceuticalintelligence.com/2013/12/23/calmodulin-and-protein-kinase-c-drive-the-ca2-regulation-of-hormone-and-neurotransmitter-release-that-triggers-ca2-stimulated-exocy - Cardiac Contractility & Myocardial Performance: Therapeutic Implications of Ryanopathy (Calcium Release-related Contractile Dysfunction) and Catecholamine Responses
Author, and Content Consultant to e-SERIES A: Cardiovascular Diseases: Justin Pearlman, MD, PhD, FACC
Author and Curator: Larry H Bernstein, MD, FCAP and Article Curator: Aviva Lev-Ari, PhD, RN
http://pharmaceuticalintelligence.com/2013/08/28/cardiac-contractility-myocardium-performance-ventricular-arrhythmias-and-non-ischemic-heart-failure-therapeutic-implications-for-cardiomyocyte-ryanopathy-calcium-release-related-contractile/ - Role of Calcium, the Actin Skeleton, and Lipid Structures in Signaling and Cell Motility
Author and Curator: Larry H Bernstein, MD, FCAP Author: Stephen Williams, PhD, and Curator: Aviva Lev-Ari, PhD, RN
http://pharmaceuticalintelligence.com/2013/08/26/role-of-calcium-the-actin-skeleton-and-lipid-structures-in-signaling-and-cell-motility/ - Identification of Biomarkers that are Related to the Actin Cytoskeleton
Larry H Bernstein, MD, FCAP, Author and Curator
http://pharmaceuticalintelligence.com/2012/12/10/identification-of-biomarkers-that-are-related-to-the-actin-cytoskeleton/ - Advanced Topics in Sepsis and the Cardiovascular System at its End Stage
Author and Curator: Larry H Bernstein, MD, FCAP
http://pharmaceuticalintelligence.com/2013/08/18/advanced-topics-in-Sepsis-and-the-Cardiovascular-System-at-its-End-Stage/ - The Delicate Connection: IDO (Indolamine 2, 3 dehydrogenase) and Cancer Immunology
Demet Sag, PhD, Author and Curator
http://pharmaceuticalintelligence.com/2013/08/04/the-delicate-connection-ido-indolamine-2-3-dehydrogenase-and-immunology/ - IDO for Commitment of a Life Time: The Origins and Mechanisms of IDO, indolamine 2, 3-dioxygenase
Demet Sag, PhD, Author and Curator
http://pharmaceuticalintelligence.com/2013/08/04/ido-for-commitment-of-a-life-time-the-origins-and-mechanisms-of-ido-indolamine-2-3-dioxygenase/ - Confined Indolamine 2, 3 dioxygenase (IDO) Controls the Homeostasis of Immune Responses for Good and Bad
Author and Curator: Demet Sag, PhD, CRA, GCP
http://pharmaceuticalintelligence.com/2013/07/31/confined-indolamine-2-3-dehydrogenase-controls-the-hemostasis-of-immune-responses-for-good-and-bad/ - Signaling Pathway that Makes Young Neurons Connect was discovered @ Scripps Research Institute
Reporter: Aviva Lev-Ari, PhD, RN
http://pharmaceuticalintelligence.com/2013/06/26/signaling-pathway-that-makes-young-neurons-connect-was-discovered-scripps-research-institute/ - Naked Mole Rats Cancer-Free
Writer and Curator: Larry H. Bernstein, MD, FCAP
http://pharmaceuticalintelligence.com/2013/06/20/naked-mole-rats-cancer-free/ - Amyloidosis with Cardiomyopathy
Writer and Curator: Larry H. Bernstein, MD, FCAP
http://pharmaceuticalintelligence.com/2013/03/31/amyloidosis-with-cardiomyopathy/ - Liver endoplasmic reticulum stress and hepatosteatosis
Larry H Bernstein, MD, FACP
http://pharmaceuticalintelligence.com/2013/03/10/liver-endoplasmic-reticulum-stress-and-hepatosteatosis/ - The Molecular Biology of Renal Disorders: Nitric Oxide – Part III
Curator and Author: Larry H Bernstein, MD, FACP
http://pharmaceuticalintelligence.com/2012/11/26/the-molecular-biology-of-renal-disorders/ - Nitric Oxide Function in Coagulation – Part II
Curator and Author: Larry H. Bernstein, MD, FCAP
http://pharmaceuticalintelligence.com/2012/11/26/nitric-oxide-function-in-coagulation/ - Nitric Oxide, Platelets, Endothelium and Hemostasis
Curator and Author: Larry H Bernstein, MD, FACP
http://pharmaceuticalintelligence.com/2012/11/08/nitric-oxide-platelets-endothelium-and-hemostasis/ - Interaction of Nitric Oxide and Prostacyclin in Vascular Endothelium
Curator and Author: Larry H Bernstein, MD, FACP
http://pharmaceuticalintelligence.com/2012/09/14/interaction-of-nitric-oxide-and-prostacyclin-in-vascular-endothelium/ - Nitric Oxide and Immune Responses: Part 1
Curator and Author: Aviral Vatsa PhD, MBBS
http://pharmaceuticalintelligence.com/2012/10/18/nitric-oxide-and-immune-responses-part-1/ - Nitric Oxide and Immune Responses: Part 2
Curator and Author: Aviral Vatsa PhD, MBBS
http://pharmaceuticalintelligence.com/2012/10/28/nitric-oxide-and-immune-responses-part-2/ - Nitric Oxide and iNOS have Key Roles in Kidney Diseases – Part II
Curator and Author: Larry H Bernstein, MD, FACP
http://pharmaceuticalintelligence.com/2012/11/26/nitric-oxide-and-inos-have-key-roles-in-kidney-diseases/ - New Insights on Nitric Oxide donors – Part IV
Curator and Author: Larry H Bernstein, MD, FACP
http://pharmaceuticalintelligence.com/2012/11/26/new-insights-on-no-donors/ - Crucial role of Nitric Oxide in Cancer
Curator and Author: Ritu Saxena, Ph.D.
http://pharmaceuticalintelligence.com/2012/10/16/crucial-role-of-nitric-oxide-in-cancer/ - Nitric Oxide has a ubiquitous role in the regulation of glycolysis -with a concomitant influence on mitochondrial function
Curator and Author: Larry H Bernstein, MD, FACP
http://pharmaceuticalintelligence.com/2012/09/16/nitric-oxide-has-a-ubiquitous-role-in-the-regulation-of-glycolysis-with-a-concomitant-influence-on-mitochondrial-function/ - Nitric Oxide and Immune Responses: Part 2
Author and Curator: Aviral Vatsa, PhD, MBBS
http://pharmaceuticalintelligence.com/2012/10/28/nitric-oxide-and-immune-responses-part-2/ - Mitochondrial Damage and Repair under Oxidative Stress
Author and Curator: Larry H. Bernstein, MD, FCAP
http://pharmaceuticalintelligence.com/2012/10/28/mitochondrial-damage-and-repair-under-oxidative-stress/ - Is the Warburg Effect the cause or the effect of cancer: A 21st Century View?
Curator and Author: Larry H Bernstein, MD, FACP
http://pharmaceuticalintelligence.com/2012/10/17/is-the-warburg-effect-the-cause-or-the-effect-of-cancer-a-21st-century-view/ - Targeting Mitochondrial-bound Hexokinase for Cancer Therapy
Curator and Author: Ziv Raviv, PhD, RN 04/06/2013
http://pharmaceuticalintelligence.com/2013/04/06/targeting-mitochondrial-bound-hexokinase-for-cancer-therapy/ - Ubiquinin-Proteosome pathway, autophagy, the mitochondrion, proteolysis and cell apoptosis
Curator and Author: Larry H Bernstein, MD, FACP
http://pharmaceuticalintelligence.com/2012/10/30/ubiquinin-proteosome-pathway-autophagy-the-mitochondrion-proteolysis-and-cell-apoptosis/ - Ubiquitin-Proteosome pathway, Autophagy, the Mitochondrion, Proteolysis and Cell Apoptosis: Part III
Curator and Author: Larry H Bernstein, MD, FACP
http://pharmaceuticalintelligence.com/2013/02/14/ubiquinin-proteosome-pathway-autophagy-the-mitochondrion-proteolysis-and-cell-apoptosis-reconsidered/ - Biochemistry of the Coagulation Cascade and Platelet Aggregation – Part I
Curator and Author: Larry H Bernstein, MD, FACP
http://pharmaceuticalintelligence.com/2012/11/26/biochemistry-of-the-coagulation-cascade-and-platelet-aggregation/
Genomics, Transcriptomics, and Epigenetics
- What is the meaning of so many RNAs?
Writer and Curator: Larry H. Bernstein, MD, FCAP
http://pharmaceuticalintelligence.com/2014/08/06/what-is-the-meaning-of-so-many-rnas/ - RNA and the transcription the genetic code
Larry H. Bernstein, MD, FCAP, Writer and Curator
http://pharmaceuticalintelligence.com/2014/08/02/rna-and-the-transcription-of-the-genetic-code/ - A Primer on DNA and DNA Replication
Writer and Curator: Larry H. Bernstein, MD, FCAP
http://pharmaceuticalintelligence.com/2014/07/29/a_primer_on_dna_and_dna_replication/ - Pathology Emergence in the 21st Century
Author and Curator: Larry Bernstein, MD, FCAP
http://pharmaceuticalintelligence.com/2014/08/03/pathology-emergence-in-the-21st-century/ - RNA and the transcription the genetic code
Writer and Curator, Larry H. Bernstein, MD, FCAP
http://pharmaceuticalintelligence.com/2014/08/02/rna-and-the-transcription-of-the-genetic-code/ - Commentary on Biomarkers for Genetics and Genomics of Cardiovascular Disease: Views by Larry H Bernstein, MD, FCAP
Author: Larry H Bernstein, MD, FCAP
http://pharmaceuticalintelligence.com/2014/07/16/commentary-on-biomarkers-for-genetics-and-genomics-of-cardiovascular-disease-views-by-larry-h-bernstein-md-fcap/ - Observations on Finding the Genetic Links in Common Disease: Whole Genomic Sequencing Studies
Author an Curator: Larry H Bernstein, MD, FCAP
http://pharmaceuticalintelligence.com/2013/05/18/observations-on-finding-the-genetic-links/ - Silencing Cancers with Synthetic siRNAs
Larry H. Bernstein, MD, FCAP, Reviewer and Curator
http://pharmaceuticalintelligence.com/2013/12/09/silencing-cancers-with-synthetic-sirnas/ - Cardiometabolic Syndrome and the Genetics of Hypertension: The Neuroendocrine Transcriptome Control Points
Reporter: Aviva Lev-Ari, PhD, RN
http://pharmaceuticalintelligence.com/2013/12/12/cardiometabolic-syndrome-and-the-genetics-of-hypertension-the-neuroendocrine-transcriptome-control-points/ - Developments in the Genomics and Proteomics of Type 2 Diabetes Mellitus and Treatment Targets
Larry H. Bernstein, MD, FCAP, Reviewer and Curator
http://pharmaceuticalintelligence.com/2013/12/08/developments-in-the-genomics-and-proteomics-of-type-2-diabetes-mellitus-and-treatment-targets/ - CT Angiography & TrueVision™ Metabolomics (Genomic Phenotyping) for new Therapeutic Targets to Atherosclerosis
Reporter: Aviva Lev-Ari, PhD, RN
http://pharmaceuticalintelligence.com/2013/11/15/ct-angiography-truevision-metabolomics-genomic-phenotyping-for-new-therapeutic-targets-to-atherosclerosis/ - CRACKING THE CODE OF HUMAN LIFE: The Birth of BioInformatics & Computational Genomics
Genomics Curator, Larry H Bernstein, MD, FCAP
http://pharmaceuticalintelligence.com/2014/08/30/cracking-the-code-of-human-life-the-birth-of-bioinformatics-computational-genomics/ - Big Data in Genomic Medicine
Author and Curator, Larry H Bernstein, MD, FCAP
http://pharmaceuticalintelligence.com/2012/12/17/big-data-in-genomic-medicine/ - From Genomics of Microorganisms to Translational Medicine
Author and Curator: Demet Sag, PhD
http://pharmaceuticalintelligence.com/2014/03/20/without-the-past-no-future-but-learn-and-move-genomics-of-microorganisms-to-translational-medicine/ - Summary of Genomics and Medicine: Role in Cardiovascular Diseases
Author and Curator, Larry H Bernstein, MD, FCAP
http://pharmaceuticalintelligence.com/2014/01/06/summary-of-genomics-and-medicine-role-in-cardiovascular-diseases/
2012pharmaceutical
Amandeep Kaur
Aashir Awan, Phd
Abhisar Anand
Adina Hazan
Alan F. Kaul, PharmD., MS, MBA, FCCP
alexcrystal6
anamikasarkar
apreconasia
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Dror Nir
dsmolyar
Ethan Coomber
evelinacohn
Gail S Thornton
Irina Robu
jayzmit48
jdpmd
jshertok
kellyperlman
Ed Kislauskis
larryhbern
Madison Davis
marzankhan
megbaker58
ofermar2020
Dr. Pati
pkandala
Rosalind Codrington, PhD
ritusaxena
Rick Mandahl
sjwilliamspa
Srinivas Sriram
stuartlpbi
Dr. Sudipta Saha
tildabarliya
vaishnavee24
zraviv06
zs22
This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.
A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.
This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.
A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.
This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.
A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.
This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.
A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.
This is very insightful. There is no doubt that there is the bias you refer to. 42 years ago, when I was postdocing in biochemistry/enzymology before completing my residency in pathology, I knew that there were very influential mambers of the faculty, who also had large programs, and attracted exceptional students. My mentor, it was said (although he was a great writer), could draft a project on toilet paper and call the NIH. It can’t be true, but it was a time in our history preceding a great explosion. It is bizarre for me to read now about eNOS and iNOS, and about CaMKII-á, â, ã, ä – isoenzymes. They were overlooked during the search for the genome, so intermediary metabolism took a back seat. But the work on protein conformation, and on the mechanism of action of enzymes and ligand and coenzyme was just out there, and became more important with the research on signaling pathways. The work on the mechanism of pyridine nucleotide isoenzymes preceded the work by Burton Sobel on the MB isoenzyme in heart. The Vietnam War cut into the funding, and it has actually declined linearly since.
A few years later, I was an Associate Professor at a new Medical School and I submitted a proposal that was reviewed by the Chairman of Pharmacology, who was a former Director of NSF. He thought it was good enough. I was a pathologist and it went to a Biochemistry Review Committee. It was approved, but not funded. The verdict was that I would not be able to carry out the studies needed, and they would have approached it differently. A thousand young investigators are out there now with similar letters. I was told that the Department Chairmen have to build up their faculty. It’s harder now than then. So I filed for and received 3 patents based on my work at the suggestion of my brother-in-law. When I took it to Boehringer-Mannheim, they were actually clueless.